Cygnus, Becton Dickinson deal

Becton received exclusive worldwide marketing and distribution rights, excepting Japan and Korea, to CYGN's GlucoWatch continuous glucose monitoring device. CYGN is eligible to receive up front and milestone payments up to $20 million.

CYGN will receive an undisclosed percentage of profits. Eric Hecht, analyst at Morgan, Stanley, believes CYGN'S share will be about 50 percent. ...